Tags

Type your tag names separated by a space and hit enter

Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).
J Infect Dis. 2012 Dec 15; 206(12):1852-61.JI

Abstract

BACKGROUND

Cases of infection due to a novel swine-origin variant of influenza A virus subtype H3N2 (H3N2v) have recently been identified in the United States, primarily among children. We estimate levels of cross-reactive antibody to H3N2v by age and assess whether seasonal trivalent inactivated influenza vaccine (TIV), with or without adjuvant, may increase seroprotection.

METHODS

Antibody to H3N2v was assessed by hemagglutination inhibition (HI) assay and, for a subset, also by microneutralization assay. Seroprevalence and seroprotection were defined as an HI titer of ≥40, and levels were compared with those for ancestral and contemporary human strains. The analysis included 1116 sera collected during fall 2010, corresponding to approximately 100 sera per decade of life. Vaccine-induced antibody levels were also assessed in sera from 136 children aged <10 years and 65 adults aged 20-59 years before and after receipt of 2010-2011 split TIV and in sera from 182 elderly individuals aged ≥65 years before and after receipt of 2011-2012 split TIV (for 31 individuals), MF59-adjuvanted TIV (for 72), or unadjuvanted subunit TIV (for 79).

RESULTS

The overall prevalence of HI titers of ≥40 against A(H3N2)v was 25%. No children aged <5 years and <20% of individuals aged ≤14 years or ≥40 years had an HI titer of ≥40. Conversely, among individuals aged 15-39 years, half of teens and adults showed H3N2v seroprotection. Following TIV receipt, <15% of individuals in any vaccine group developed a 4-fold increase in antibody level.

CONCLUSIONS

A substantial proportion of adolescents and young adults have cross-reactive antibody against emerging H3N2v, whereas children and older adults show broad susceptibility. Recent formulations of TIV do not substantially increase seroprotection. A specific vaccine would be needed if H3N2v establishes epidemic spread.

CLINICAL TRIALS REGISTRATION

NCT01140009 and NCT01368796.

Authors+Show Affiliations

British Columbia Centre for Disease Control, Canada. danuta.skowronski@bccdc.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22872731

Citation

Skowronski, Danuta M., et al. "Cross-reactive and Vaccine-induced Antibody to an Emerging Swine-origin Variant of Influenza a Virus Subtype H3N2 (H3N2v)." The Journal of Infectious Diseases, vol. 206, no. 12, 2012, pp. 1852-61.
Skowronski DM, Janjua NZ, De Serres G, et al. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis. 2012;206(12):1852-61.
Skowronski, D. M., Janjua, N. Z., De Serres, G., Purych, D., Gilca, V., Scheifele, D. W., Dionne, M., Sabaiduc, S., Gardy, J. L., Li, G., Bastien, N., Petric, M., Boivin, G., & Li, Y. (2012). Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). The Journal of Infectious Diseases, 206(12), 1852-61. https://doi.org/10.1093/infdis/jis500
Skowronski DM, et al. Cross-reactive and Vaccine-induced Antibody to an Emerging Swine-origin Variant of Influenza a Virus Subtype H3N2 (H3N2v). J Infect Dis. 2012 Dec 15;206(12):1852-61. PubMed PMID: 22872731.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). AU - Skowronski,Danuta M, AU - Janjua,Naveed Z, AU - De Serres,Gaston, AU - Purych,Dale, AU - Gilca,Vladimir, AU - Scheifele,David W, AU - Dionne,Marc, AU - Sabaiduc,Suzana, AU - Gardy,Jennifer L, AU - Li,Guiyun, AU - Bastien,Nathalie, AU - Petric,Martin, AU - Boivin,Guy, AU - Li,Yan, Y1 - 2012/08/07/ PY - 2012/8/9/entrez PY - 2012/8/9/pubmed PY - 2013/1/26/medline SP - 1852 EP - 61 JF - The Journal of infectious diseases JO - J. Infect. Dis. VL - 206 IS - 12 N2 - BACKGROUND: Cases of infection due to a novel swine-origin variant of influenza A virus subtype H3N2 (H3N2v) have recently been identified in the United States, primarily among children. We estimate levels of cross-reactive antibody to H3N2v by age and assess whether seasonal trivalent inactivated influenza vaccine (TIV), with or without adjuvant, may increase seroprotection. METHODS: Antibody to H3N2v was assessed by hemagglutination inhibition (HI) assay and, for a subset, also by microneutralization assay. Seroprevalence and seroprotection were defined as an HI titer of ≥40, and levels were compared with those for ancestral and contemporary human strains. The analysis included 1116 sera collected during fall 2010, corresponding to approximately 100 sera per decade of life. Vaccine-induced antibody levels were also assessed in sera from 136 children aged <10 years and 65 adults aged 20-59 years before and after receipt of 2010-2011 split TIV and in sera from 182 elderly individuals aged ≥65 years before and after receipt of 2011-2012 split TIV (for 31 individuals), MF59-adjuvanted TIV (for 72), or unadjuvanted subunit TIV (for 79). RESULTS: The overall prevalence of HI titers of ≥40 against A(H3N2)v was 25%. No children aged <5 years and <20% of individuals aged ≤14 years or ≥40 years had an HI titer of ≥40. Conversely, among individuals aged 15-39 years, half of teens and adults showed H3N2v seroprotection. Following TIV receipt, <15% of individuals in any vaccine group developed a 4-fold increase in antibody level. CONCLUSIONS: A substantial proportion of adolescents and young adults have cross-reactive antibody against emerging H3N2v, whereas children and older adults show broad susceptibility. Recent formulations of TIV do not substantially increase seroprotection. A specific vaccine would be needed if H3N2v establishes epidemic spread. CLINICAL TRIALS REGISTRATION: NCT01140009 and NCT01368796. SN - 1537-6613 UR - https://www.unboundmedicine.com/medline/citation/22872731/Cross_reactive_and_vaccine_induced_antibody_to_an_emerging_swine_origin_variant_of_influenza_A_virus_subtype_H3N2__H3N2v__ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jis500 DB - PRIME DP - Unbound Medicine ER -